Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis

Samuel Bitoun , Matthieu Roulleaux-Dugage, Marie Naigeon , Caroline de Oliveira , Caroline Berthot , Xavier Mariette , Gaetane Nocturne , Nathalie Chaput

BMJ Journals | . 2026 May 20;12(2):e006537.  doi: 10.1136/rmdopen-2025-006537. Affiliations Expand PMID: 42161414 PMCID: PMC13201991 DOI: 10.1136/rmdopen-2025-006537

Les immunothérapies sont l’avenir de la rhumatologie.

Hélène Joubert

Le Quotidien du Médecin. | 2026 Mar 31. Version en ligne. URL : lequotidiendumedecin.fr. Sujets : Immunothérapie ; Rhumatologie ; Maladies auto-immunes.

See all Publications